Our preliminary clinical data show that patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T radioligand therapy, as demonstrated by tumour progression, may benefit from a change in treatment to the novel radiohybrid PSMA ligand, [177Lu]Lu-rhPSMA-10.1. Here, FOLH1 is linked to neoplasm.